Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies

Xiao-qing Yao; Yun-hui Zhang; Wei Long; Pei-xun Liu

doi:10.1007/s11655-012-1001-6

Your Location：

Home >

Browse articles >

Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies

Updated：2021-08-27

- Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies
- Chinese Journal of Integrative Medicine Vol. 18, Issue 3, Pages: 209-213(2012)
- Affiliations：
  
  1. College of Pharmaceutical Science and Technology, Tianjin University,Tianjin,China
  2. Tianjin Chase Sun Pharmaceutical Co., Ltd.,Tianjin,China
  3. Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College,Tianjin,China
- Author bio：
- Funds：
  
  Supported by Tianjin Key Technology Research & Development Program (No. 07ZCKFSH00200)
- DOI：10.1007/s11655-012-1001-6
  CLC：
- Published：2012，
  
  Published Online：2 April 2012，
Scan for full text
Yao, Xq., Zhang, Yh., Long, W. et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies., Chin. J. Integr. Med. 18, 209–213 (2012). https://doi.org/10.1007/s11655-012-1001-6

Xiao-qing Yao, Yun-hui Zhang, Wei Long, et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies. [J]. Chinese Journal of Integrative Medicine 18(3):209-213(2012)
Yao, Xq., Zhang, Yh., Long, W. et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies., Chin. J. Integr. Med. 18, 209–213 (2012). https://doi.org/10.1007/s11655-012-1001-6 DOI：

Xiao-qing Yao, Yun-hui Zhang, Wei Long, et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies. [J]. Chinese Journal of Integrative Medicine 18(3):209-213(2012) DOI： 10.1007/s11655-012-1001-6.

摘要

To observe the in vivo effects of oxysophoridine on hepatocellular carcinoma in mice and to study the related mechanisms. C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously

then divided into 5 groups (14 per group)

and treated with oxysophoridine (50

100

or 150 mg/kg) or cisplatin (4 mg/kg) for 10 days. Inhibitory rate of tumor

body weight gain

and influence indices on internal organs (liver

spleen and thymus) were evaluated. The differentially expressed genes between the oxysophoridine-treated group

and the control group were analyzed using cDNA microarray and quantitative real-time PCR (qRT-PCR) experiments. Compared with the tumor weight of the control group (2.75±0.66 g)

oxysophoridine significantly suppressed hepatocellular carcinoma growth in mice (P <0.01)

with 0.82±0.36 g

0.57±0.22 g

and 1.22±0.67 g for the tumor weight in the low

moderate

and high dose treatment group

respectively. The moderate dose led to the highest inhibitory rate

79.3%. Observation of body weight gain and influence on three organs showed that compared with cisplatin

oxysophoridine produced fewer side effects in vivo. cDNA microarray and qRT-PCR showed that the most significant differentially expressed genes in the tumor samples of oxysophoridine-treated mice were mostly involved in regulating apoptosis

with the Tnfrsf11b (osteoprotegerin) gene being the most significantly affected. Oxysophoridine was a promising compound for developing drugs against hepatocellular carcinoma

and its anti-hepatoma effect was probably related to osteoprotegerin activation.

Abstract

To observe the in vivo effects of oxysophoridine on hepatocellular carcinoma in mice and to study the related mechanisms. C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously

then divided into 5 groups (14 per group)

and treated with oxysophoridine (50

100

or 150 mg/kg) or cisplatin (4 mg/kg) for 10 days. Inhibitory rate of tumor

body weight gain

and influence indices on internal organs (liver

spleen and thymus) were evaluated. The differentially expressed genes between the oxysophoridine-treated group

and the control group were analyzed using cDNA microarray and quantitative real-time PCR (qRT-PCR) experiments. Compared with the tumor weight of the control group (2.75±0.66 g)

oxysophoridine significantly suppressed hepatocellular carcinoma growth in mice (P <0.01)

with 0.82±0.36 g

0.57±0.22 g

and 1.22±0.67 g for the tumor weight in the low

moderate

and high dose treatment group

respectively. The moderate dose led to the highest inhibitory rate

79.3%. Observation of body weight gain and influence on three organs showed that compared with cisplatin

with the Tnfrsf11b (osteoprotegerin) gene being the most significantly affected. Oxysophoridine was a promising compound for developing drugs against hepatocellular carcinoma

and its anti-hepatoma effect was probably related to osteoprotegerin activation.

关键词

oxysophoridinehepatocellular carcinomacDNA microarrayqRT-PCRTnfrsf11bosteoprotegerin

Keywords

oxysophoridinehepatocellular carcinomacDNA microarrayqRT-PCRTnfrsf11bosteoprotegerin

references

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–156.

Cherqui D. Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998;5:35–40.

Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485–1491.

Tan A, Aucejo F, Kim R. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma? Oncology 2010;78:161–171.

Atta-Ur-Rahman A, Choudhary MI, Parvez K, Ahmed A, Akhtar F, Nur EAM, Hassan NM. Quinolizidine alkaloids from Sophora alopecuroides. J Nat Prod 2000;63:190–192.

Sun J, Mao J, Liu X, Wang Y, Sun Y, He Z. Separation and mechanism elucidation for six structure-like matrinetype alkaloids by micellar liquid chromatography. J Sep Sci 2009;32:2043–2050.

Ding PL, Liao ZX, Huang H, Zhou P, Chen DF. (+)-12α-hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens. Bioorg Med Chem Lett 2006;16:1231–1235.

Zhang HM, Li HQ. Anti-arrhythmic effects of sophoridine and oxysophoridine. Acta Pharmacol Sin 1999;20:517–520.

Huang X, Li B. Effects of six alkaloids of Sophora Alopecuroides on LTC4 and LTB4. Chin Tradit Patent Med (Chin) 2003;25:824–826.

Yu JQ, Jiang YX. Effects of oxysophoridine on Glu and GABA immuno-reaction positive neurons in cortex and hippocampus of rats. China J Chin Mater Med (Chin) 2006;31:1611–1614.

Yu J, Li Y, Zhao C, Gong X, Liu J, Wang F, Jiang Y. Effect of oxysophoridine on electric activities and its power spectrum of reticulum formation in rats. China J Chin Mater Med (Chin) 2010;35:1170–1172.

Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001;120:955–966.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.

Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.

Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117–5123.

Lu TY, Kao CF, Lin CT, Huang DY, Chiu CY, Huang YS, Wu HC. DNA methylation and histone modification regulate silencing of OPG during tumor progression. J Cell Biochem 2009;108:315–325.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Bear bile powder (熊胆粉) induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway

Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial

Effects of Huogu I Formula (活骨I方) on correlated factors of bone regeneration in chickens with steroid-induced necrosis of femoral head

Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine

Total saponin from root of Actinidia Valvata Dunn prevents the metastasis of human hepatocellular carcinoma cells

Related Author

No data

Related Institution

Fujian Guizhentang Pharmaceutical Co., Ltd.

Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine

Fujian Academy of Integrative Medicine

Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰